Brain+ A/S has entered a partnership with Quiddity Health to prepare for market entry and commercial scaling of CST-Therapist Companion. Quiddity Health has a stated purpose of Sales Acceleration for Proven Healthcare Solutions - Build Pipeline, Grow Revenue, and they have successfully helped several new digital health and therapeutic solutions be established on the UK healthcare market, including Headspace, Hedia and Radiobotics, and they currently serve 30+ proven digital health companies for their UK commercial scaling. Quiddity Health operate mainly on a revenue sharing model, meaning that they take a risk in their partnerships and therefore perform due diligence on the companies and on the relevance and scaling potential of their solutions, before committing to partnerships.

Through 2023, Brain+ has developed a significantly upgraded version 2.0 of CST-Therapist Companion, its digital solution to support the delivery of Cognitive Stimulation Therapy (CST) to people with mild to moderate dementia. A UK adopted version of CST-Therapist Companion v2.0 is planned ready for commercial release in third quarter 2024. This includes getting medical device certification under EU MDR (class 1) as well as under corresponding UK regulations and meeting all other relevant regulatory and quality requirements.

Having medical device status opens access to a broader range of healthcare customers and payers, including the National Health Service in the UK, also providing a stronger value proposition and hence pricing. potential for the product. The Quiddity Health and Brain+ partnership starts with an initial effort to co-create the commercial strategy for CST-Therapist Companion in the UK and start preparing market entry of the product.

This includes a targeted go-to-market plan and the build-up of relevant pre-sale UK customer engagements. Based on Quiddity experience, the expectations are to be able to close the first sale in fourth quarter 2024 and to have a pipeline of leads for additional sales to be realized in first quarter 2025. Following commercial release, Quiddity will take the role as Brain+' full-scale commercial partner in the UK to execute on the commercial scaling strategy on the operational sales side.